In a recent legal development, a federal judge in Delaware ruled against Mallinckrodt Pharmaceuticals in its effort to stop Airgas Healthcare, a French industrial gas company, from selling a generic version of its inhaled nitric oxide treatment. The court found that Mallinckrodt was unable to provide sufficient evidence that Airgas had infringed on its patents or that the company would face irreparable harm if the generic product were allowed on the market.
This case highlights the ongoing challenges faced by pharmaceutical companies in protecting their proprietary products from generic competitors. For further details, the original article can be accessed at Law360.